6306-75-8

Basic information

• Product Name: 5-methyl-1-propan-2-yl-pyrimidine-2,4-dione
• Synonyms: 5-methyl-1-propan-2-yl-pyrimidine-2,4-dione
• CAS NO: 6306-75-8
• Molecular Formula: C8H12N2O2
• Molecular Weight: 168.19
• Mol File: 6306-75-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.25g/cm³
• Refractive Index: 1.63
• CAS DataBase Reference: 5-methyl-1-propan-2-yl-pyrimidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-1-propan-2-yl-pyrimidine-2,4-dione(6306-75-8)
• EPA Substance Registry System: 5-methyl-1-propan-2-yl-pyrimidine-2,4-dione(6306-75-8)

Safety Data

• Hazardous Substances Data: 6306-75-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H19N3O3S/c1-14(23-24-21(26)19-7-4-12-28-19)16-5-3-6-17(13-16)22-20(25)15-8-10-18(27-2)11-9-15/h3-13H,1-2H3,(H,22,25)(H,24,26)

Upstream product

• 6306-74-7 1-isopropyl-5-methyl-dihydro-pyrimidine-2,4-dione 
• 75-30-9 2-iodo-propane 
• 51-21-8 5-fluorouracil 

Relevant articles and documents

Compound for treating pneumonia and application thereof

The invention discloses a compound for treating pneumonia and application thereof, and relates to the technical field of medicines. The compound for treating pneumonia is a heterocyclic compound, a pharmaceutically acceptable salt of the heterocyclic compound and/or a pharmaceutically acceptable carrier of the heterocyclic compound. The compound for treating pneumonia has a significant improvementeffect on bacterial pneumonia, viral pneumonia, fungal pneumonia, immune pneumonia, mycoplasma pneumonia, chlamydia pneumonia and other pathogen pneumonia, and especially can significantly improve pathological damage of viral bacterial pneumonia. The heterocyclic compound involved in the compound for treating pneumonia is simple in synthesis method, is suitable for industrial production, and is more stable than natural analogues; the activity of the compound is remarkably superior to that of ribavirin, oseltamivir, cefazolin and penicillin G which are clinically first-line medicines, and theactivity of the compound is also remarkably superior to that of purine analogues A, B and C.